Advertisement
Health & Fitness
Business

Can premature ejaculation spray rescue the sagging fortune of this Hong Kong firm and improve the sex lives of Asian men?

  • Mining-turned-health care firm is banking on the prescription-only spray to boost its bottom line
  • Its Hong Kong-traded shares have lost 44pc since it acquired developer of the spray

3-MIN READ3-MIN
Erectile dysfunction medical concept as a group of men standing casting long shadows but one individual male casts a short shadow as a urology and psychological symbol for erection problems or sexual performance in a 3D illustration style. Photo Alamy
Eric Ng
Regent Pacific Group, a Hong Kong-listed company that transformed itself three times over three decades, said it had secured regulatory approvals and a licence to sell a spray for treating premature ejaculation in Hong Kong and Macau, and not a moment too soon.

The company licensed Shanghai Fosun Pharmaceutical’s unit Wanbang Pharmaceutical last month to help it obtain approval and sell Fortacin, a prescription-only topical spray in mainland China. Separately, Regent licensed Taiwan-listed Orient EuroPharma to distribute the drug in Hong Kong, Macau, Taiwan and six Southeast Asian markets.

“We hope our product will alleviate any distress [that accompanies] sexual dysfunction, and bring confidence back to the [sufferer] so that he can perform in line with the average male,” Regent’s chief executive officer Jamie Gibson said in an interview with the South China Morning Post.

The approvals and licensing would offer an additional option to existing treatments to men who suffer from premature ejaculation, a form of sexual dysfunction that also includes impotence, which attracts more public attention due to the blockbuster drug Viagra approved for use two decades ago.

Select Voice
Select Speed
1x
AI-generated voice